Becton Dickinson And Co: A $5.3 Billion Quarter Signals Limited Growth Momentum

Becton, Dickinson and Company reported first quarter fiscal 2026 revenue of $5.3 billion, reflecting a 0.4% increase overall and a 2.5% growth in its restructured portfolio referred to as New BD. The company completed the combination of its Life Sciences business with Waters Corporation ahead of schedule, signaling a strategic pivot toward becoming a focused pure-play MedTech company. As part of this transaction, Becton, Dickinson and Company received a $4 billion cash distribution, allocating half toward share repurchases and the remainder to debt reduction. The company continues to emphasize a capital allocation approach centered on share buybacks, dividend reliability, and targeted acquisitions in high-growth markets. New BD’s growth was broad-based, with double-digit expansion in biologic drug delivery, advanced tissue regeneration, PureWick urinary incontinence products, and pharmacy automation.